Tissue Expression of MMP-9, TIMP-1, RECK, and MiR338-3p in Prostate Gland: Can It Predict Cancer?

Overview

Journal Mol Biol Res Commun

Specialty Molecular Biology

Date 2022 Jan 31

PMID 35097136

Authors

Rodolfo Pacheco de Moraes

Ruan Pimenta

Fernando Noboru Cabral Mori

Gabriel Arantes Dos Santos

Nayara Izabel Viana

Vanessa Ribeiro Guimaraes

Juliana Alves de Camargo

Katia Ramos Moreira Leite

Miguel Srougi

William Carlos Nahas

Sabrina T Reis

Affiliations

Soon will be listed here.

Abstract

Prostate cancer is the most frequent malignancy affecting men worldwide. Due to the low sensitivity and specificity of the prostate-specific antigen test and the digital rectal exam as screening modalities, several alternatives are being studied. This study aimed to evaluate the application of MMP-9 and its regulators (TIMP-1, RECK, and miR-338-3p) as diagnostic and prognostic indicators of prostate cancer. A total of 134 randomly selected patients under investigation for prostate cancer submitted to a transrectal ultrasound-guided prostate biopsy were enrolled in the study; of these, 61 were positive for the disease (cases), and 73 were negative (control group). The tissue samples were further analyzed by gene and miR-338-3p expression analysis using qRT-PCR (one randomly selected fragment of each patient). Approximately 58% of the patients with prostate cancer presented MMP9 upregulation, while 73%, 65%, and 69% downregulated IMP-1, RECK, and miR-338-3p, respectively. MiR-338-3p was expressed at lower levels in patients with PSA concentrations exceeding 20 ng/mL (p=0.045) and abnormal DRE (p=0.006), while the RECK was more expressed in patients with abnormal DRE (p=0.01). We found that most patients with prostate cancer overexpressed MMP-9; on the other hand, most of them underexpressed TIMP-1, RECK, and miR-338-3p. MiR-338-3p presented as a possible predictor of poor prognosis. Further studies are warranted to evaluate these biomarkers as prognosis factors better.

Citing Articles

MiR-21 Regulates Growth and Migration of Cervical Cancer Cells by RECK Signaling Pathway.

Aguilar-Martinez S, Campos-Viguri G, Medina-Garcia S, Garcia-Flores R, Deas J, Gomez-Ceron C Int J Mol Sci. 2024; 25(7).

PMID: 38612895 PMC: 11012906. DOI: 10.3390/ijms25074086.

Prostate cancer research: tools, cell types, and molecular targets.

Liu A Front Oncol. 2024; 14:1321694.

PMID: 38595814 PMC: 11002103. DOI: 10.3389/fonc.2024.1321694.

Intratumoral Restoration of miR-137 Plus Cholesterol Favors Homeostasis of the miR-137/Coactivator p160/AR Axis and Negatively Modulates Tumor Progression in Advanced Prostate Cancer.

Pimenta R, Mioshi C, Goncalves G, Candido P, Camargo J, Guimaraes V Int J Mol Sci. 2023; 24(11).

PMID: 37298588 PMC: 10253647. DOI: 10.3390/ijms24119633.

Characterization of Immune-Based Molecular Subtypes and Prognostic Model in Prostate Adenocarcinoma.

Guo L, Kang Y, Xia D, Ren Y, Yang X, Xiang Y Genes (Basel). 2022; 13(6).

PMID: 35741849 PMC: 9223199. DOI: 10.3390/genes13061087.

References

Rabien A, Ergun B, Erbersdobler A, Jung K, Stephan C . RECK overexpression decreases invasive potential in prostate cancer cells. Prostate. 2011; 72(9):948-54. DOI: 10.1002/pros.21498. View

Seubert B, Grunwald B, Kobuch J, Cui H, Schelter F, Schaten S . Tissue inhibitor of metalloproteinases (TIMP)-1 creates a premetastatic niche in the liver through SDF-1/CXCR4-dependent neutrophil recruitment in mice. Hepatology. 2014; 61(1):238-48. PMC: 4280301. DOI: 10.1002/hep.27378. View

Babichenko I, Andriukhin M, Pulbere S, Loktev A . Immunohistochemical expression of matrix metalloproteinase-9 and inhibitor of matrix metalloproteinase-1 in prostate adenocarcinoma. Int J Clin Exp Pathol. 2015; 7(12):9090-8. PMC: 4313967. View

Rawla P . Epidemiology of Prostate Cancer. World J Oncol. 2019; 10(2):63-89. PMC: 6497009. DOI: 10.14740/wjon1191. View

Oh J, Takahashi R, Kondo S, Mizoguchi A, Adachi E, Sasahara R . The membrane-anchored MMP inhibitor RECK is a key regulator of extracellular matrix integrity and angiogenesis. Cell. 2001; 107(6):789-800. DOI: 10.1016/s0092-8674(01)00597-9. View

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

Reis S, Leite K, Piovesan L, Pontes-Junior J, Viana N, Abe D . Increased expression of MMP-9 and IL-8 are correlated with poor prognosis of Bladder Cancer. BMC Urol. 2012; 12:18. PMC: 3424138. DOI: 10.1186/1471-2490-12-18. View

Thompson I, Ankerst D, Chi C, Lucia M, Goodman P, Crowley J . Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower. JAMA. 2005; 294(1):66-70. DOI: 10.1001/jama.294.1.66. View

Sartakhti J, Manshaei M, Sadeghi M . MMP-TIMP interactions in cancer invasion: An evolutionary game-theoretical framework. J Theor Biol. 2016; 412:17-26. DOI: 10.1016/j.jtbi.2016.09.019. View

10.

Schoots I, Roobol M, Nieboer D, Bangma C, Steyerberg E, Hunink M . Magnetic resonance imaging-targeted biopsy may enhance the diagnostic accuracy of significant prostate cancer detection compared to standard transrectal ultrasound-guided biopsy: a systematic review and meta-analysis. Eur Urol. 2014; 68(3):438-50. DOI: 10.1016/j.eururo.2014.11.037. View

11.

Reis S, Viana N, Iscaife A, Pontes-Junior J, Dip N, Antunes A . Loss of TIMP-1 immune expression and tumor recurrence in localized prostate cancer. Int Braz J Urol. 2016; 41(6):1088-95. PMC: 4756933. DOI: 10.1590/S1677-5538.IBJU.2014.0451. View

12.

Greene K, Albertsen P, Babaian R, Carter H, Gann P, Han M . Prostate specific antigen best practice statement: 2009 update. J Urol. 2012; 189(1 Suppl):S2-S11. DOI: 10.1016/j.juro.2012.11.014. View

13.

Miah S, Hosking-Jervis F, Connor M, Eldred-Evans D, Shah T, Arya M . A Multicentre Analysis of the Detection of Clinically Significant Prostate Cancer Following Transperineal Image-fusion Targeted and Nontargeted Systematic Prostate Biopsy in Men at Risk. Eur Urol Oncol. 2019; 3(3):262-269. DOI: 10.1016/j.euo.2019.03.005. View

14.

Naji L, Randhawa H, Sohani Z, Dennis B, Lautenbach D, Kavanagh O . Digital Rectal Examination for Prostate Cancer Screening in Primary Care: A Systematic Review and Meta-Analysis. Ann Fam Med. 2018; 16(2):149-154. PMC: 5847354. DOI: 10.1370/afm.2205. View

15.

Leite K, Reis S, Viana N, Morais D, Moura C, Silva I . Controlling RECK miR21 Promotes Tumor Cell Invasion and Is Related to Biochemical Recurrence in Prostate Cancer. J Cancer. 2015; 6(3):292-301. PMC: 4317766. DOI: 10.7150/jca.11038. View

16.

Liu H, Gao P . The roles of microRNAs related with progression and metastasis in human cancers. Tumour Biol. 2016; 37:15383–15397. DOI: 10.1007/s13277-016-5436-9. View

17.

Bakkar A, Alshalalfa M, Petersen L, Abou-Ouf H, Al-Mami A, Hegazy S . microRNA 338-3p exhibits tumor suppressor role and its down-regulation is associated with adverse clinical outcome in prostate cancer patients. Mol Biol Rep. 2016; 43(4):229-40. DOI: 10.1007/s11033-016-3948-4. View

18.

Reis S, Pontes-Junior J, Antunes A, de Sousa-Canavez J, DallOglio M, Passerotti C . MMP-9 overexpression due to TIMP-1 and RECK underexpression is associated with prognosis in prostate cancer. Int J Biol Markers. 2011; 26(4):255-61. DOI: 10.5301/JBM.2011.8831. View

19.

Chen R, Sheng L, Zhang H, Ji M, Qian W . miR-15b-5p facilitates the tumorigenicity by targeting RECK and predicts tumour recurrence in prostate cancer. J Cell Mol Med. 2018; 22(3):1855-1863. PMC: 5824417. DOI: 10.1111/jcmm.13469. View

20.

Huang X, Chen J, Wang Q, Chen X, Wen L, Chen L . miR-338-3p suppresses invasion of liver cancer cell by targeting smoothened. J Pathol. 2011; 225(3):463-72. DOI: 10.1002/path.2877. View